Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy

被引：9

作者：

Morimoto, Masahiro ^{[1
]}

Nishino, Kazumi ^{[2
]}

Wada, Kentaro ^{[1
]}

Imamura, Fumio ^{[2
]}

Konishi, Koji ^{[1
]}

Kuhara, Hanako ^{[2
]}

Tamiya, Motohiro ^{[2
]}

Inoue, Takako ^{[2
]}

Kunimasa, Kei ^{[2
]}

Kimura, Madoka ^{[2
]}

Hirata, Takero ^{[3
,4
]}

Kanayama, Naoyuki ^{[1
]}

Toratani, Masayasu ^{[1
]}

Kawachi, Hayato ^{[2
]}

Ohira, Kika ^{[2
]}

Nakanishi, Erina ^{[1
,4
]}

Ohira, Shingo ^{[1
]}

Sagawa, Tomohiro ^{[1
]}

Miyazaki, Masayoshi ^{[1
]}

Matsunaga, Takashi ^{[3
]}

Kumagai, Toru ^{[2
]}

Teshima, Teruki ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Dept Radiat Oncol, Osaka, Japan

[2] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

[3] Osaka Int Canc Inst, Dept Med Informat, Osaka, Japan

[4] Osaka Univ, Dept Radiat Oncol, Grad Sch Med, Osaka, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 12期

关键词：

Volumetric modulated arc therapy (VMAT); intensity modulated radiation therapy (IMRT); involved field radiotherapy irradiation (IFR-IFI); twice-daily thoracic radiotherapy (BID-TRT); accelerated hyperfractionated thoracic radiotherapy (AHTRT); anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs); CONCURRENT CHEMOTHERAPY; STAGE IIIA; RADIATION; RADIOTHERAPY; SURVIVAL; COPD;

D O I：

10.21873/anticanres.14720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The aim of this retrospective study was to detect the frequency, reasons, and significant factors for not receiving immunotherapy after chemoradiotherapy in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Thirty-four patients with NSCLC received definitive chemoradiotherapy. The endpoint of this study was receiving durvalumab within 45 days after chemoradiotherapy for NSCLC. Results: Twenty-five of 34 (73%) patients received immunotherapy within 45 days after chemoradiotherapy. The reasons for not receiving immunotherapy were radiation pneumonitis (50%), radiation esophagitis (10%), and four other reasons (40%). Univariate analysis showed that significant factors for not receiving immunotherapy were elective nodal irradiation (ENI)+ and chronic obstructive pulmonary disease (COPD)+. The rate of immunotherapy was 100% (17/17 cases) in the COPD- and ENI- group, and 16% (1/6 cases) in the COPD+ and ENI+ group. Conclusion: ENI for NSCLC complicated with COPD decreased the rate of immunotherapy after definitive chemoradiotherapy.

引用

页码：6957 / 6970

页数：14

共 50 条

[21] Histological Difference in Outcomes of Definitive Chemoradiotherapy for non-small cell Lung Cancer
Hitoshi, I.
Matsuo, Y.
Ohtsu, S.
Sakamoto, T.
Mizowaki, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2176 - S2177
[22] Salvage Surgery After Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer
Lampridis, Savvas
ANNALS OF THORACIC SURGERY, 2021, 112 (06): : 2108 - 2108
[23] Efficacy of Immune Checkpoint Inhibitor on Non-Small Cell Lung Cancer with Chronic Obstructive Pulmonary Disease
Zhang, Huohuo
Li, Weimin
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[24] The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non-small cell lung cancer
Shimizu, Masamitsu
Miyanaga, Akihiko
Seike, Masahiro
Matsuda, Kuniko
Matsumoto, Masaru
Noro, Rintaro
Fujita, Kazue
Mano, Yoko
Furuya, Nobuhiko
Kubota, Kaoru
Gemma, Akihiko
THORACIC CANCER, 2022, 13 (13) : 1940 - 1947
[25] Chronic obstructive pulmonary disease and comorbidities' influence on mortality in non-small cell lung cancer patients
Media, Ara Shwan
Persson, Martin
Tajhizi, Navid
Weinreich, Ulla Moller
ACTA ONCOLOGICA, 2019, 58 (08) : 1102 - 1106
[26] Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease
Chang, Qing
Li, Jiaqi
Zhu, Yan
Qiang, Huiping
Lu, Haijiao
Shen, Yinchen
Wang, Shuyuan
Qian, Jialin
Chu, Tianqing
JOURNAL OF THORACIC DISEASE, 2024, 16 (11)
[27] Pulmonary resection of non-small cell lung cancer (NSCLC) can be performed safely following definitive chemoradiotherapy
Page, Brandi R.
Blitz, Maurice
Vallieres, Eric
Louie, Brain E.
Aye, Ralph W.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S301 - S301
[28] Feasibility of Salvage Pulmonary Resection after Definitive Chemoradiotherapy for Advanced Non-Small Cell Lung Cancer Patients
Kobayashi, A. K.
Horinouchi, H.
Ito, Y.
Oe, Y.
Uchida, S.
Asakura, K.
Yoshida, Y.
Nakagawa, K.
Watanabe, S.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1563 - S1563
[29] Clinicopathologic features of patients with non-small cell lung cancer and chronic obstructive pulmonary disease undergoing lung cancer surgery
Radosavljevic, Sladjana
Andrijevic, Ilija
Matijasevic, Jovan
Obradovic, Dusanka
Krunic, Stoja
Ilic, Senka Milutinov
Bokan, Aleksandar
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[30] Feasibility of Proton Therapy for Elective Nodal Irradiation in Patients With Locally Advanced Non-small Cell Lung Cancer
Kesarwala, A. H.
Ko, C.
O'Meara, W. P.
Ning, H.
Haglund, K. E.
Xanthopoulos, E.
Rengan, R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S577 - S578

← 1 2 3 4 5 →